Liver Cancer, Metastatic Cancer
Conditions
Keywords
advanced adult primary liver cancer, liver metastases, localized unresectable adult primary liver cancer, recurrent adult primary liver cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with liposomal doxorubicin may increase the effectiveness of the drug and kill more tumor cells. PURPOSE: This phase I trial is studying the best dose of liposomal doxorubicin when given with radiofrequency ablation in treating patients with primary or metastatic liver tumors.
Detailed description
OBJECTIVES: * Determine the maximum tolerated dose of heat activated doxorubicin HCl liposome when combined with radiofrequency ablation in patients with primary or metastatic tumors of the liver. * Determine the pharmacokinetics and pharmacodynamics of this drug in these patients. OUTLINE: This is a dose-escalation study of heat activated doxorubicin HCl liposome. Patients receive doxorubicin HCl liposome IV over 30 minutes. Approximately 15 minutes after the beginning of the doxorubicin HCl liposome infusion, patients undergo radiofrequency ablation with needles inserted into the tumor(s) and heated to the target temperature for approximately 12-60 minutes. Cohorts of 3-6 patients receive escalating doses of heat activated doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. Patients are followed at 28 days, every 3 months for 1 year, and then every 6 months for 2 years. PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 2 years.
Interventions
PROCEDUREradiofrequency ablation
Sponsors
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed tumor of the liver * Primary or metastatic disease * No more than 4 lesions * No single lesion \> 7 cm in maximum diameter * Not a candidate for curative surgical resection due to tumor histology or prior surgery PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 3 months Hematopoietic * Platelet count ≥ 75,000/mm\^3 * WBC ≥ 1,500/mm\^3 * Hemoglobin ≥ 10 g/dL (transfusions to attain levels ≥ 10g/dL allowed) Hepatic * Bilirubin ≤ 2.0 mg/dL * PT or PTT ≤ 1.5 times control (except for patients receiving anticoagulation therapy for an unrelated medical condition \[e.g., atrial fibrillation\]) Renal * Creatinine ≤ 2.5 mg/dL Cardiovascular * See Hepatic * Ejection fraction ≥ 50% by MUGA * No congestive heart failure * No myocardial infarction within the past 6 months * No cerebral vascular accident within the past 6 months * No life-threatening cardiac arrhythmia Other * Weight \< 136 kg * Glucose ≤ 300 mg/dL * No uncontrolled diabetes * No known serious uncontrolled reaction (e.g., anaphylaxis) to contrast agents used in this study * No known allergy to egg or egg products * No other serious medical illness * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent interferon * No live vaccines (for immunosuppressed patients only) during and for 30 days after study treatment Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * See Disease Characteristics Other * More than 3 weeks since prior therapy for liver tumor(s) * More than 3 weeks since prior systemic therapy for non-life-threatening extrahepatic disease and recovered * No other concurrent systemic therapy * No administration of any of the following medications during and for 30 days after study treatment: * Cyclosporine * Phenobarbital * Phenytoin * Streptozocin * No concurrent administration of any of the following medications: * Amphotericin B by injection * Antithyroid agents for overactive thyroid * Azathioprine * Chloramphenicol * Colchicine * Flucytosine * Ganciclovir * Plicamycin * Zidovudine * Probenecid * Sulfinpyrazone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose of heat-activated doxorubicin HCL liposome | — |
| Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion | — |
Countries
China, United States
Outcome results
None listed